Login / Signup

Testosterone nadir and clinical outcomes in patients with advanced prostate cancer: Post hoc analysis of triptorelin pamoate Phase III studies.

Laurence H KlotzTri Tat
Published in: BJUI compass (2024)
Low nadir testosterone achieved during treatment with the LHRH agonist triptorelin was associated with improved OS and DSS in patients with advanced prostate cancer.
Keyphrases
  • prostate cancer
  • phase iii
  • radical prostatectomy
  • open label
  • replacement therapy
  • clinical trial
  • double blind
  • phase ii
  • placebo controlled
  • randomized controlled trial
  • study protocol